CG Oncology, Inc..
CGON.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing oncolytic immunotherapies for patients with bladder cancer. Their lead product candidate, cretostimogene grenadenorepvec (creto), is an oncolytic adenovirus immunotherapy designed to select...Show More
Better Health for All
-20
CG Oncology's core business is entirely focused on developing cretostimogene grenadenorepvec, a potential bladder-sparing therapeutic for bladder cancer.
1
However, the company explicitly states that this product is an investigational candidate and its safety and efficacy have not been established by the FDA or any other health authority, leading to a neutral score for its current health impact.
2
As a clinical-stage company, it has no commercialized products and therefore no revenue from products with negative health outcomes.
3
The company has initiated an Expanded Access Program (EAP) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and have exhausted other treatment options, and the PIVOT-006 trial focuses on intermediate-risk NMIBC, a population estimated to be greater than 50,000 patients in the US alone.
4
However, the EAP is for patients who have exhausted all approved options and are not eligible for traditional clinical trials, indicating a focus on a specific, limited subset of vulnerable patients.
5
The company states a belief in pursuing a clinical program that supports equity and quality of care for all patients and is committed to evaluating EAP requests in a fair and equitable manner, but there is no quantitative evidence of the scale or funding of these programs.
6
Information about the EAP and clinical studies is available on www.clinicaltrials.gov and www.cgoncology.com.
7
Clinical trials, including the Phase 3 PIVOT-006 study with over 360 patients across more than 90 sites, require the requesting physician to obtain appropriate regulatory and ethics committee approvals and comply with regulatory obligations, including patient consent, monitoring, and safety reporting.
8
Fair Money & Economic Opportunity
0
No evidence available to assess CG Oncology, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
CG Oncology has no regulatory actions, violations, fines, or compliance issues mentioned in the provided articles.
1
The company offers comprehensive health insurance, including PPO & HDHP plans from Cigna/Principal, HSA with annual company contributions, and FSA/FSA-DCA.
2
These benefits are provided to employees, including those in temporary roles with full benefits, indicating approximately 90% of the workforce is covered. Additionally, the company provides 100% company Safe Harbor match up to 4% of base salary for 401K, unlimited flexible time off, and 14 holidays in 2025.
3
The company also offers wellness programs, an employee assistance program, and mental health resources.
4
CG Oncology states it is an Equal Opportunity Employer and is committed to building a diverse team.
5
The company's workforce includes less than 5% in flexible roles, all with full safeguards.
Fair Trade & Ethical Sourcing
0
No evidence available to assess CG Oncology, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
The company has not reported any ethics-related regulatory fines in the past three years.
1
It has not had any financial restatements in the past five years.
2
A Whistleblower Policy is in place,
3
and an ethics hotline is implemented for anonymous reporting,
4
with the Audit Committee responsible for investigations;
5
however, there is no evidence of training frequency or program effectiveness measurement. The Board of Directors has 6 out of 9 directors (66.7%) identified as independent under Nasdaq rules.
6
The company has a Code of Conduct and Ethics,
7
which provides a framework for ethical business decisions and compliance with laws,
8
but there is no evidence of training frequency or effectiveness metrics. Ernst & Young LLP has been the independent registered public accounting firm since 2021,
9
and the Audit Committee oversees financial reporting,
10
but the extent of audit coverage is not specified. There is no evidence of a recognized transparency benchmark score,
11
ESG controversy score,
12
or median complaint resolution time.
13
Kind to Animals
0
No specific data or concrete facts were found in the provided articles regarding CGON.US's performance, policies, or practices related to animal welfare, animal testing, or animal-free alternatives.
1
While some articles discuss general industry trends, regulatory changes, and alternative testing methods, none of this information is attributed directly to CGON.US.
2
Therefore, all KPIs for the 'Kind to Animals' value must be omitted due to a lack of direct evidence.
No War, No Weapons
0
The provided articles, including an IPO registration statement and clinical trial results, contain no specific data or information regarding CG Oncology's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' ethical value.
1
Therefore, no KPIs could be scored based on the evidence provided.
Planet-Friendly Business
0
The company's Nominating and Corporate Governance Committee is responsible for reviewing and assisting the Board with oversight of environmental, social, and governance (ESG) matters, and reports periodically on these efforts.
1
However, the provided articles do not contain specific, quantifiable environmental performance metrics such as greenhouse gas emissions, renewable energy usage, water consumption, waste diversion, or details on climate-related targets, policies, or initiatives that align with the provided KPIs.
2
Respect for Cultures & Communities
0
No specific evidence was found in the provided articles regarding CG Oncology's performance on any of the KPIs related to 'Respect for Cultures & Communities'. The articles primarily focus on the company's clinical trials, product development, regulatory designations, and general employment benefits, without detailing community engagement, cultural impact assessments, local employment ratios, or other relevant metrics. While one article discusses diversity, equity, and inclusion initiatives, these examples pertain to other cancer centers and organizations, not CG Oncology directly.
1
Safe & Smart Tech
-30
The company's website is not designed to respond to 'Do Not Track' signals, indicating minimal user control over data.
1
However, it does state that it does not knowingly collect personal information from children under thirteen years of age and does not share personal information for direct marketing purposes as defined by California Civil Code Section 1798.83.
2
The company also mentions compliance with various U.S. federal, state, and foreign healthcare laws and regulations, as well as export control, import, tax, employment, immigration, and labor laws, and its cybersecurity framework is modeled after NIST CSF principles.
3
Zero Waste & Sustainable Products
0
No relevant data was found in the provided articles regarding CGON.US's performance on any of the Zero Waste & Sustainable Products KPIs.
1
The articles explicitly state that they contain no information specific to the company or the requested metrics.
2